• Rotigotine Analytical Methods: Impurities and Stability

  2026-09-11

  The reference review integrates pharmacopoeial and literature methods for measuring Rotigotine in raw material and transdermal patches, with particular attention to related impurities, oxidative degradation, and enantiomeric purity. Its practical contribution is a quality-control framework for developing stability-indicating assays while highlighting the limited pharmacokinetic and toxicological characterization of Rotigotine impurities.

• Fulvestrant: An ERα Probe for Cancer and Immunity

  2026-09-11

  Fulvestrant (ICI 182,780) is more than an estrogen receptor degrader for advanced breast cancer. This article explains how to use its receptor-level perturbation logic to distinguish ERα, GPR30, and endoplasmic reticulum stress effects in translational assays.

• Nebivolol Hydrochloride: β1 Research Guide

  2026-09-10

  Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist for receptor-signaling and cardiovascular pharmacology research. Product data report an IC50 of 0.8 nM, while a 2025 yeast study found no evidence that nebivolol inhibits TOR under its tested conditions.

• GSK126 and the Translational Logic of EZH2 Biology

  2026-09-10

  GSK126 offers translational researchers a precise way to interrogate EZH2-driven chromatin repression, connecting tumor biology with immune-regulatory models. This thought-leadership perspective links PRC2 mechanism, cancer epigenetics research, experimental design, and the broader relevance of H3K27me3-dependent gene control.

• TAK1–YAP Control of Gastric Cancer Stem Cells

  2026-09-09

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as an upstream regulator of YAP stability in gastric cancer stem cells. Its findings connect IL-6–induced TAK1 expression with YAP preservation, SOX2/SOX9 transcription, stem-cell self-renewal, and gastric tumorigenesis, providing a mechanistic framework for cancer research and future treatment-response studies.

• Gly-Gly-Phe-Gly (GGFG) Linker Workflow

  2026-09-09

  Gly-Gly-Phe-Gly (GGFG) provides a compact, sequence-defined spacer for drug conjugation research, peptide engineering, and biomaterial construction. This workflow connects practical handling and coupling controls with mechanistic assay design inspired by multiple myeloma research, while clearly separating linker performance from disease biology.

• Rotigotine Analytical Methods and Impurity Control

  2026-09-08

  This review consolidates chromatographic and related analytical methods for Rotigotine raw material, transdermal formulations, impurities, degradation products, and enantiomeric purity. Its main practical contribution is to connect pharmacopoeial procedures with literature methods, while identifying unresolved stability, pharmacokinetic, and toxicological questions that remain important for Parkinson’s disease research.

• Nebivolol hydrochloride in β1 Signaling Assays

  2026-09-08

  Nebivolol hydrochloride provides a precise β1-adrenoceptor antagonist tool for dissecting cardiac signaling while serving as a useful negative comparator in mTOR/TOR discovery workflows. This article combines formulation guidance, receptor-assay design, yeast counter-screening, and troubleshooting for more interpretable cardiovascular pharmacology research.

• EDC.HCl: Practical In Vitro Coupling Guide

  2026-09-07

  EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation with primary amines in peptide synthesis, bioconjugation, and related laboratory workflows. This guidance is for controlled in vitro use only; the supplied dossier reports no in vivo or clinical data and recommends avoiding long-term storage of prepared solutions.

• Diphenyleneiodonium Chloride in ROS Assays

  2026-09-07

  Diphenyleneiodonium chloride is a powerful but nonselective probe for separating redox-enzyme activity from cAMP signaling. This article translates recent iron–ROS–ferroptosis research into practical assay-design decisions, controls, and interpretation strategies.

• MVC Activates RhoA/ROCK1 to Disrupt Tight Junctions

  2026-09-05

  The reference study identifies a mechanism by which Minute Virus of Canines (MVC) activates the RhoA/ROCK1/MLC2 axis, remodels tight junctions, and promotes occludin-associated viral entry. Its combination of VP2–ROCK1 interaction mapping, pathway inhibition, permeability analysis, and viral replication readouts provides a mechanistic framework for studying MVC infection in canine cells.

• GPR35–KLF5 Repair Circuitry in Colitis

  2026-09-04

  A 2026 Cell Death & Disease study identifies a tryptophan–kynurenine–kynurenic acid sensing mechanism in which GPR35 activates KLF5-dependent epithelial repair through PI3K–AKT–mTOR signaling. The work connects metabolic damage sensing with intestinal epithelial cell proliferation and migration, offering a mechanistic framework for ulcerative colitis research while highlighting important translational limitations.

• Foretinib: Mapping Growth Arrest vs Cell Death

  2026-09-04

  Foretinib and GSK1363089 research are examined through a phenotype-first framework that separates tumor cell growth inhibition from cell death. Learn how to integrate kinase potency, motility assays, and metastasis models for more interpretable cancer research.

• DMG-PEG2000-NH2: From Linker to Assay Design

  2026-09-03

  DMG-PEG2000-NH2 is an NH2-PEG derivative that connects lipid-based delivery design with rigorous biomolecular assay planning. This article explains how to evaluate its reaction logic, formulation role, controls, and the limits of translating medicinal-chemistry evidence into delivery experiments.

• Sabutoclax: Measuring Apoptosis Beyond Viability

  2026-09-03

  Sabutoclax is a pan-Bcl-2 inhibitor whose apparent potency can reflect both growth arrest and cell death. This guide applies a refined response-measurement framework to apoptosis induction in cancer cells, helping researchers design more informative assays and interpret preclinical data.

7737 records 1/516 page Next 12345 下5页 Last page